Market Cap 159.87B
Revenue (ttm) 23.88B
Net Income (ttm) 3.90B
EPS (ttm) N/A
PE Ratio 30.14
Forward PE 30.15
Profit Margin 16.33%
Debt to Equity Ratio 0.33
Volume 1,153,812
Avg Vol 3,853,172
Day's Range N/A - N/A
Shares Out 706.35M
Stochastic %K 55%
Beta 0.89
Analysts Strong Sell
Price Target $255.38

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
KingdomTrading
KingdomTrading Dec. 16 at 12:49 PM
$DHR Price: 228.53 Entry: 224.52 Exit: 217.54 Duration: 3D The content provided on https://www.ztradez.net is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:22 PM
Wells Fargo updates rating for Danaher ( $DHR ) to Equal-Weight, target set at 230 → 240.
0 · Reply
parcha
parcha Dec. 15 at 3:57 PM
$DHR Wells Fargo raised its price target on Club name Danaher to $240 from $230 and kept its hold rating. The life sciences company is turning the corner. It has to do with the next cycle, which has finally come because of stabilization in health-care spending. Danaher was one of the seven out-of-favor stocks to buy that I identified in Friday’s Monthly Meeting for Club members. https://www.cnbc.com/2025/12/15/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:40 AM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $226.33, showing a neutral RSI of 48.51, indicating no immediate overbought or oversold conditions. The stock is positioned above the 30-day MA of $222.17 and the 50-day MA of $218.20, suggesting a bullish short-term trend. The 60-day high of $234.99 presents a significant resistance level, while the low of $180.03 provides a solid support base. Directional Bias: With the stock trading above key moving averages and the RSI indicating potential for upward movement, we lean bullish. Trade Plan: - Suggested Entry: $227.00 - Stop Loss: $222.00 (below the 30-day MA) - Take Profit Targets: 1. $232.00 (2.2% gain) 2. $238.00 (4.9% gain) 3. $265.00 (17% gain) This plan allows for a strategic entry while targeting significant upside potential. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
nathan_moore19
nathan_moore19 Dec. 12 at 5:40 PM
$DHR Mainz Biomed is a clean microcap story to hold because it’s scalable by channels and guidelines, USPSTF pushed screening to 45+, and the stock structure stays light and reactive
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:32 PM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $231.26, showing bullish momentum with an RSI of 63.5, indicating it is approaching overbought territory but still has room to run. The price is above both the 30-day MA of $221.76 and the 50-day MA of $217.86, suggesting a strong upward trend. The recent 60-day high of $234.99 provides a key resistance level. Directional Bias: Bullish. The current price action above the moving averages and the proximity to the 60-day high supports a positive outlook. Trade Plan: - Suggested Entry: $231.50 - Take Profit Target 1: $235.00 (1.08% ROI) - Take Profit Target 2: $240.00 (3.77% ROI) - Take Profit Target 3: $270.00 (16.73% ROI) - Stop Loss: $227.00 (1.93% risk) This plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. Monitor price action closely for any adjustments. https://privateprofiteers.com
0 · Reply
hoganbear
hoganbear Dec. 10 at 7:39 PM
$DHR OH FUCK YES!!!
0 · Reply
ripster47
ripster47 Dec. 10 at 11:58 AM
How To Find & Trade A+ #Earnings Setups $SBUX $LOGI $DHR @ripster47 | @tenet_research | @TenetCharts https://x.com/i/status/1998573506280534066
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:37 AM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $223.71, showing a neutral RSI of 46.84, indicating a lack of strong momentum. The stock is above its 30-day moving average (MA30) at $220.75 and significantly above its 50-day moving average (MA50) at $216.85, suggesting a bullish short-term outlook. The recent high of $234.99 presents a potential resistance level. Directional Bias: The stock has room to move upward given its position relative to the MAs and the 60-day high-low range. A breakout above recent highs could signal further upside. Trade Plan: - Suggested Entry: $224.00 - Stop Loss: $216.00 (3.6% risk) - Take Profit Targets: 1. $230.00 (2.68% gain) 2. $236.00 (5.36% gain) 3. $261.00 (16.67% gain) With a potential ROI of over 17% on the third target, this trade offers a favorable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 9 at 2:13 PM
$DHR Danny Hur ALWAYS disappoints
1 · Reply
Latest News on DHR
Danaher Announces Quarterly Dividend

Dec 9, 2025, 4:15 PM EST - 6 days ago

Danaher Announces Quarterly Dividend


3 More Good Stocks to Invest In After Earnings

Nov 18, 2025, 4:29 PM EST - 27 days ago

3 More Good Stocks to Invest In After Earnings

FTNT LPLA


The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 4 weeks ago

The Big 3: TMO, DHR, VLO

TMO VLO


Danaher to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 4:15 PM EST - 4 weeks ago

Danaher to Present at Jefferies Global Healthcare Conference


Danaher: Regaining Growth Momentum

Oct 22, 2025, 10:49 AM EDT - 7 weeks ago

Danaher: Regaining Growth Momentum


Here's Why Shares in Danaher Got Boosted Higher Today

Oct 21, 2025, 2:17 PM EDT - 2 months ago

Here's Why Shares in Danaher Got Boosted Higher Today


Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Oct 21, 2025, 11:14 AM EDT - 2 months ago

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript


Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:23 AM EDT - 2 months ago

Danaher Sales and Profit Rise on Bioprocessing Momentum


Danaher Reports Third Quarter 2025 Results

Oct 21, 2025, 6:00 AM EDT - 2 months ago

Danaher Reports Third Quarter 2025 Results


Danaher Stock: Monopoly Margins, Discounted Price

Oct 15, 2025, 10:25 AM EDT - 2 months ago

Danaher Stock: Monopoly Margins, Discounted Price


3 Top Healthcare Stocks to Buy in October

Oct 13, 2025, 5:21 AM EDT - 2 months ago

3 Top Healthcare Stocks to Buy in October

NVO UNH


4 Stocks That Aren't Too Hot to Buy Right Now

Oct 6, 2025, 2:45 PM EDT - 2 months ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU


Danaher: Balanced Portfolio With Upside Potential In 2026

Oct 1, 2025, 6:33 AM EDT - 2 months ago

Danaher: Balanced Portfolio With Upside Potential In 2026


Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 23, 2025, 4:15 PM EDT - 3 months ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call


Analysts' Top S&P 500 Stocks to Buy Now

Sep 11, 2025, 2:26 PM EDT - 3 months ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 3 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX GRAL ILMN IONS MRNA RGEN


iA Global Buys the Dip in Danaher's Stock Price

Aug 13, 2025, 10:58 AM EDT - 4 months ago

iA Global Buys the Dip in Danaher's Stock Price


Danaher Stock Closes Near Day's High After Key Trading Signal

Aug 4, 2025, 7:13 AM EDT - 4 months ago

Danaher Stock Closes Near Day's High After Key Trading Signal


Danaher Appoints Jonathan Leiken as General Counsel

Jul 31, 2025, 4:15 PM EDT - 4 months ago

Danaher Appoints Jonathan Leiken as General Counsel


Danaher Q2 2025 Update

Jul 24, 2025, 3:30 PM EDT - 5 months ago

Danaher Q2 2025 Update


Danaher Raises 2025 Earnings Outlook

Jul 22, 2025, 5:04 PM EDT - 5 months ago

Danaher Raises 2025 Earnings Outlook


Danaher Beats Q2 Revenue, EPS Forecasts

Jul 22, 2025, 4:12 PM EDT - 5 months ago

Danaher Beats Q2 Revenue, EPS Forecasts


Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 1:18 PM EDT - 5 months ago

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript


Cramer's Stop Trading: Danaher

Jul 22, 2025, 10:33 AM EDT - 5 months ago

Cramer's Stop Trading: Danaher


Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:02 AM EDT - 5 months ago

Danaher Announces Transition Plan for Chief Financial Officer


Danaher Reports Second Quarter 2025 Results

Jul 22, 2025, 6:00 AM EDT - 5 months ago

Danaher Reports Second Quarter 2025 Results


KingdomTrading
KingdomTrading Dec. 16 at 12:49 PM
$DHR Price: 228.53 Entry: 224.52 Exit: 217.54 Duration: 3D The content provided on https://www.ztradez.net is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:22 PM
Wells Fargo updates rating for Danaher ( $DHR ) to Equal-Weight, target set at 230 → 240.
0 · Reply
parcha
parcha Dec. 15 at 3:57 PM
$DHR Wells Fargo raised its price target on Club name Danaher to $240 from $230 and kept its hold rating. The life sciences company is turning the corner. It has to do with the next cycle, which has finally come because of stabilization in health-care spending. Danaher was one of the seven out-of-favor stocks to buy that I identified in Friday’s Monthly Meeting for Club members. https://www.cnbc.com/2025/12/15/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:40 AM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $226.33, showing a neutral RSI of 48.51, indicating no immediate overbought or oversold conditions. The stock is positioned above the 30-day MA of $222.17 and the 50-day MA of $218.20, suggesting a bullish short-term trend. The 60-day high of $234.99 presents a significant resistance level, while the low of $180.03 provides a solid support base. Directional Bias: With the stock trading above key moving averages and the RSI indicating potential for upward movement, we lean bullish. Trade Plan: - Suggested Entry: $227.00 - Stop Loss: $222.00 (below the 30-day MA) - Take Profit Targets: 1. $232.00 (2.2% gain) 2. $238.00 (4.9% gain) 3. $265.00 (17% gain) This plan allows for a strategic entry while targeting significant upside potential. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
nathan_moore19
nathan_moore19 Dec. 12 at 5:40 PM
$DHR Mainz Biomed is a clean microcap story to hold because it’s scalable by channels and guidelines, USPSTF pushed screening to 45+, and the stock structure stays light and reactive
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:32 PM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $231.26, showing bullish momentum with an RSI of 63.5, indicating it is approaching overbought territory but still has room to run. The price is above both the 30-day MA of $221.76 and the 50-day MA of $217.86, suggesting a strong upward trend. The recent 60-day high of $234.99 provides a key resistance level. Directional Bias: Bullish. The current price action above the moving averages and the proximity to the 60-day high supports a positive outlook. Trade Plan: - Suggested Entry: $231.50 - Take Profit Target 1: $235.00 (1.08% ROI) - Take Profit Target 2: $240.00 (3.77% ROI) - Take Profit Target 3: $270.00 (16.73% ROI) - Stop Loss: $227.00 (1.93% risk) This plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. Monitor price action closely for any adjustments. https://privateprofiteers.com
0 · Reply
hoganbear
hoganbear Dec. 10 at 7:39 PM
$DHR OH FUCK YES!!!
0 · Reply
ripster47
ripster47 Dec. 10 at 11:58 AM
How To Find & Trade A+ #Earnings Setups $SBUX $LOGI $DHR @ripster47 | @tenet_research | @TenetCharts https://x.com/i/status/1998573506280534066
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:37 AM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $223.71, showing a neutral RSI of 46.84, indicating a lack of strong momentum. The stock is above its 30-day moving average (MA30) at $220.75 and significantly above its 50-day moving average (MA50) at $216.85, suggesting a bullish short-term outlook. The recent high of $234.99 presents a potential resistance level. Directional Bias: The stock has room to move upward given its position relative to the MAs and the 60-day high-low range. A breakout above recent highs could signal further upside. Trade Plan: - Suggested Entry: $224.00 - Stop Loss: $216.00 (3.6% risk) - Take Profit Targets: 1. $230.00 (2.68% gain) 2. $236.00 (5.36% gain) 3. $261.00 (16.67% gain) With a potential ROI of over 17% on the third target, this trade offers a favorable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 9 at 2:13 PM
$DHR Danny Hur ALWAYS disappoints
1 · Reply
hoganbear
hoganbear Dec. 9 at 2:12 PM
$DHR Danny Hurr is an absolute fucking tank $SPY
0 · Reply
erevnon
erevnon Dec. 9 at 12:50 PM
Goldman Sachs initiates coverage on Danaher $DHR at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 12:38 PM
Goldman Sachs has updated their rating for Danaher ( $DHR ) to Buy with a price target of 265.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:24 PM
Actionable Trade Alert for $DHR: Market Context: $DHR closed at $225.4, showing strength above its 30-day moving average (MA30) of $220.69 and 50-day moving average (MA50) of $216.12. The RSI at 57.79 indicates bullish momentum, suggesting potential for further upside. Directional Bias: The stock is currently trading near its 60-day high of $234.99, indicating a bullish trend. The distance from the 60-day low of $180.03 provides a favorable risk-reward setup. Trade Plan: - Suggested Entry: $225.4 - Stop Loss: $218.0 (approximately 3.5% below entry) - Take Profit Targets: 1. Target 1: $230.0 (2.4% gain) 2. Target 2: $235.0 (4.3% gain) 3. Target 3: $264.0 (17.1% gain) With a stop loss at $218.0, achieving the third target would yield an ROI of over 17%. Monitor the trade closely for volatility as indicated by the ATR of 4.54. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:25 AM
Actionable Trade Alert for $DHR: Market Context: $DHR's last close at $227.13 indicates a strong position above both the 30-day MA of $220.49 and the 50-day MA of $214.41. The RSI at 59.6 suggests bullish momentum, nearing overbought territory but not yet a reversal signal. The recent 60-day high of $234.99 presents a key resistance level. Directional Bias: The upward trend is supported by the proximity to the 60-day high and the positive positioning relative to moving averages. The ATR of 4.94 indicates reasonable volatility for potential gains. Trade Plan: - Suggested Entry: $227.50 - Stop Loss: $222.50 (risking $5, approx. 2.2% of entry) - Take Profit Targets: - Target 1: $232.00 (2% gain) - Target 2: $237.00 (4.2% gain) - Target 3: $266.00 (17% gain) With this plan, we aim for a minimum of 17% ROI on the third target while maintaining a controlled risk. https://privateprofiteers.com
0 · Reply
TipRanks
TipRanks Dec. 4 at 11:15 AM
Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks https://www.tipranks.com/news/article/morgan-stanley-ups-the-ante-on-these-2-life-science-tool-stocks $DHR $A
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:33 PM
Morgan Stanley has adjusted their stance on Danaher ( $DHR ), setting the rating to Overweight with a target price of 270.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 2 at 5:13 PM
$DHR Share Price: $226.14 Contract Selected: Dec 26, 2025 $225 Calls Buy Zone: $6.03 – $7.46 Target Zone: $10.73 – $13.11 Potential Upside: 68% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 28 at 8:43 PM
$DHR Current Stock Price: $227.07 Contracts to trade: $230 DHR Nov 28 2025 Call Entry: $0.05 Exit: $0.07 ROI: 64% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
actio
actio Nov. 27 at 2:40 PM
$DHR A big future over the next ten years.
0 · Reply
topstockalerts
topstockalerts Nov. 25 at 8:25 PM
After completing the spinoff of its Electronics unit, Qnity, DuPont may finally be positioned to operate like a long-term “compounder,” similar to Berkshire Hathaway and Danaher. Deutsche Bank argues the new, slimmer DuPont—focused on industrial and water-filtration markets with brands like Kevlar, Tyvek, and TapTec—offers high quality, solid growth prospects, strong free-cash-flow potential, and an attractive valuation. Despite years of restructurings that reduced the combined market value of the DuPont/Dow family of companies, investors are looking ahead. Adjusted for the Qnity spin, DuPont shares are up about 21% year to date. Sales are expected to be around $7 billion in 2026, significantly below pre-spin levels, but off a smaller base that could support steadier growth. The stock trades at roughly 11× expected 2026 Ebitda, well below peers at about 15.5×, while earnings per share are projected to grow 8% to 10% annually. $DD.X $BRK.B $DHR $Q
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 20 at 5:59 PM
$DHR Share Price: $222.01 Contract Selected: Dec 12, 2025 $220 Calls Buy Zone: $6.54 – $8.09 Target Zone: $11.68 – $14.28 Potential Upside: 69% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply